Relevant bibliographies by topics / Localized Drug Delivery System

Academic literature on the topic 'Localized Drug Delivery System'

Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Localized Drug Delivery System.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Localized Drug Delivery System"

1

Malik, Mohit Saini Jitender K. "Novel Drug Delivery System Microsphere: A Review." SAR Journal of Anatomy and Physiology 3, no. 2 (April 29, 2022): 9–16. http://dx.doi.org/10.36346/sarjap.2022.v03i02.001.

Full text
Abstract:
The concept of targeted drug delivery is designed to attempt to concentrate the drug in the tissues of interest while reducing the relative concentration of the drug in the remaining tissues. As a result, the drug is localized to the targeted site. Therefore, the surrounding tissues are not affected by the drug. Therefore, carrier technology provides an intelligent approach to drug delivery by coupling drugs to carrier particles such as microspheres, nanoparticles, liposomes, niosomes, etc., modulating the release and absorption characteristics drug revenue. Microspheres are typically free-flowing powders made of proteins or synthetic polymers that are biodegradable in nature and ideally have a particle size of less than 200 μm. It is a reliable way to deliver drugs to the target site with specificity, if altered, and to maintain the desired concentration at the site of interest without side effects. Microspheres have received a great deal of attention not only for sustained release but also for targeting anti-cancer drugs to tumors. In the future, by combining various strategies, microspheres will occupy a central place in the delivery of new drugs, especially in the classification of diseased cells, diagnostics, genes and genetic material, safe, targeted and effective in vivo delivery and supplements in miniature versions of diseased organs and tissues in the body.
APA, Harvard, Vancouver, ISO, and other styles
2

Vigata, Margaux, Cathal D. O’Connell, Silvia Cometta, Dietmar W. Hutmacher, Christoph Meinert, and Nathalie Bock. "Gelatin Methacryloyl Hydrogels for the Localized Delivery of Cefazolin." Polymers 13, no. 22 (November 16, 2021): 3960. http://dx.doi.org/10.3390/polym13223960.

Full text
Abstract:
The tuneability of hydrogels renders them promising candidates for local drug delivery to prevent and treat local surgical site infection (SSI) while avoiding the systemic side-effects of intravenous antibiotic injections. Here, we present a newly developed gelatin methacryloyl (GelMA)-based hydrogel drug delivery system (GelMA-DDS) to locally deliver the broad-spectrum antibiotic cefazolin for SSI prophylaxis and treatment. Antibiotic doses from 3 µg to 90 µg were loaded in photocrosslinked GelMA hydrogel discs with 5 to 15% w/v polymer concentration and drug encapsulation efficiencies, mechanical properties, crosslinking and release kinetics, as well as bacterial growth inhibition were assessed. Our results demonstrate that all GelMA groups supported excellent drug encapsulation efficiencies of up to 99%. Mechanical properties of the GelMA-DDS were highly tuneable and unaffected by the loading of small to medium doses of cefazolin. The diffusive and the proteolytic in vitro drug delivery of all investigated cefazolin doses was characterized by a burst release, and the delivered cefazolin amount was directly proportional to the encapsulated dose. Accelerated enzymatic degradation of the GelMA-DDS followed zero-order kinetics and was dependent on both the cefazolin dose and GelMA concentration (3–13 h). Finally, we demonstrate that cefazolin delivered from GelMA induced a dose-dependent antibacterial efficacy against S. aureus, in both a broth and a diffusive assay. The cefazolin-loaded GelMA-DDS presented here provides a highly tuneable and easy-to-use local delivery system for the prophylaxis and treatment of SSI.
APA, Harvard, Vancouver, ISO, and other styles
3

Singh, Ranjit, and S. P. Vyas. "Topical liposomal system for localized and controlled drug delivery." Journal of Dermatological Science 13, no. 2 (November 1996): 107–11. http://dx.doi.org/10.1016/s0923-1811(96)00508-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Colon, Marlyn, Eva Christabel Williams, Ryan Toomey, and Norma Alcantar. "Localized Drug Delivery System For The Treatment Of Cancer." Biophysical Journal 96, no. 3 (February 2009): 687a. http://dx.doi.org/10.1016/j.bpj.2008.12.3629.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mhambi, Sinaye, David Fisher, Moise B. Tchoula Tchokonte, and Admire Dube. "Permeation Challenges of Drugs for Treatment of Neurological Tuberculosis and HIV and the Application of Magneto-Electric Nanoparticle Drug Delivery Systems." Pharmaceutics 13, no. 9 (September 15, 2021): 1479. http://dx.doi.org/10.3390/pharmaceutics13091479.

Full text
Abstract:
The anatomical structure of the brain at the blood–brain barrier (BBB) creates a limitation for the movement of drugs into the central nervous system (CNS). Drug delivery facilitated by magneto-electric nanoparticles (MENs) is a relatively new non-invasive approach for the delivery of drugs into the CNS. These nanoparticles (NPs) can create localized transient changes in the permeability of the cells of the BBB by inducing electroporation. MENs can be applied to deliver antiretrovirals and antibiotics towards the treatment of human immunodeficiency virus (HIV) and tuberculosis (TB) infections in the CNS. This review focuses on the drug permeation challenges and reviews the application of MENs for drug delivery for these diseases. We conclude that MENs are promising systems for effective CNS drug delivery and treatment for these diseases, however, further pre-clinical and clinical studies are required to achieve translation of this approach to the clinic.
APA, Harvard, Vancouver, ISO, and other styles
6

Christabel Williams, Eva, Ryan Toomey, and Norma Alcantar. "Double Packaged System for Localized Drug Delivery for Ovarian Cancer." Biophysical Journal 98, no. 3 (January 2010): 503a. http://dx.doi.org/10.1016/j.bpj.2009.12.2738.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Quan, N., and C. M. Blatteis. "Microdialysis: A system for localized drug delivery into the brain." Brain Research Bulletin 22, no. 4 (April 1989): 621–25. http://dx.doi.org/10.1016/0361-9230(89)90080-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Gao, Weiwei, Yue Zhang, Qiangzhe Zhang, and Liangfang Zhang. "Nanoparticle-Hydrogel: A Hybrid Biomaterial System for Localized Drug Delivery." Annals of Biomedical Engineering 44, no. 6 (March 7, 2016): 2049–61. http://dx.doi.org/10.1007/s10439-016-1583-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Vigata, Margaux, Christoph Meinert, Stephen Pahoff, Nathalie Bock, and Dietmar W. Hutmacher. "Gelatin Methacryloyl Hydrogels Control the Localized Delivery of Albumin-Bound Paclitaxel." Polymers 12, no. 2 (February 24, 2020): 501. http://dx.doi.org/10.3390/polym12020501.

Full text
Abstract:
Hydrogels are excellent candidates for the sustained local delivery of anticancer drugs, as they possess tunable physicochemical characteristics that enable to control drug release kinetics and potentially tackle the problem of systemic side effects in traditional chemotherapeutic delivery. Yet, current systems often involve complicated manufacturing or covalent bonding processes that are not compatible with regulatory or market reality. Here, we developed a novel gelatin methacryloyl (GelMA)-based drug delivery system (GelMA-DDS) for the sustained local delivery of paclitaxel-based Abraxane®, for the prevention of local breast cancer recurrence following mastectomy. GelMA-DDS readily encapsulated Abraxane® with a maximum of 96% encapsulation efficiency. The mechanical properties of the hydrogel system were not affected by drug loading. Tuning of the physical properties, by varying GelMA concentration, allowed tailoring of GelMA-DDS mesh size, where decreasing the GelMA concentration provided overall more sustained cumulative release (significant differences between 5%, 10%, and 15%) with a maximum of 75% over three months of release, identified to be released by diffusion. Additionally, enzymatic degradation, which more readily mimics the in vivo situation, followed a near zero-order rate, with a total release of the cargo at various rates (2–14 h) depending on GelMA concentration. Finally, the results demonstrated that Abraxane® delivery from the hydrogel system led to a dose-dependent reduction of viability, metabolic activity, and live-cell density of triple-negative breast cancer cells in vitro. The GelMA-DDS provides a novel and simple approach for the sustained local administration of anti-cancer drugs for breast cancer recurrence.
APA, Harvard, Vancouver, ISO, and other styles
10

Ingale, Dipit Jagannath, N. H. Aloorkar, A. S. KulkarnI, and R. A. Patil Patil. "Microsponges as Innovative Drug Delivery Systems." International Journal of Pharmaceutical Sciences and Nanotechnology 5, no. 1 (May 31, 2012): 1597–606. http://dx.doi.org/10.37285/ijpsn.2012.5.1.2.

Full text
Abstract:
Transdermal drug delivery system (TDDS) is not practicable for delivery of materials whose final target is skin itself. Controlled release of drugs onto the epidermis with assurance that the drug remains primarily localized and does not enter the systemic circulation in significant amounts is a challenging area of research. Microsponges are highly porous micro-sized particles with a unique ability for entrapping active pharmaceutical ingredients. To control the delivery rate of active agents to a predetermined site in human body has been one of the biggest challenges faced by scientists. Microsponges are safe biologically and offer unique advantage of programmable release. This technology offers entrapment of ingredients and is believed to contribute towards reduced side effects, improved stability, increased elegance and enhanced formulation flexibility. This technology is being used for topical formulations and also for oral administration. The present review describes microsponge technology including its preparation, characterization, programmable parameters and release mechanism of microsponge drug delivery system.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Localized Drug Delivery System"

1

Rodriguez, Lidia Betsabe. "Controlled Release System for Localized and Sustained Drug Delivery Applications." University of Toledo / OhioLINK, 2013. http://rave.ohiolink.edu/etdc/view?acc_num=toledo1365107103.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Falahat, Rana. "Tunable Nano-Delivery System for Cancer Treatment: A New Approach for Targeted Localized Drug Delivery." Scholar Commons, 2016. http://scholarcommons.usf.edu/etd/6234.

Full text
Abstract:
Localized drug delivery systems have been widely studied as potential replacements for conventional chemotherapy with the capability of providing sustained and controlled drug release in specific targeted sites. They offer numerous benefits over conventional chemotherapy such as enhancing the stability of embedded drugs and preserving their anticancer activity, providing sustained and controlled drug release in the tumor site, reducing toxicity and diminishing subsequent side effects, minimizing the drug loss, averting the need for frequent administrations, and minimizing the cost of therapy. The aim of this study is to develop a localized drug delivery system with niosomes embedded in a chitosan hydrogel with targeting capabilities. The incorporation of niosomes into a chitosan hydrogel has several advantages over each individually being used. First, embedding niosomes in a chitosan hydrogel can yield control over drug release especially for small molecule drugs. Second, chitosan hydrogel may improve the release time and dosage of drugs from niosomes by protecting them with an extra barrier, resulting in tunable release rates. Third, as a localized delivery system, chitosan hydrogels can prevent the migration of niosomes away from the targeted tumor sites. Finally, chitosan has mucoadhesive property which can be used in the targeting of the tumor cells with the mucin over expression. To enhance the specific targeting, the capacity of chitosan to target MUC1 overexpression in cancer cells will be analyzed. Similarly, the incorporation of chlorotoxin in this system will be achieved and evaluated. Chlorotoxin, a 36-amino acid peptide, is purified from Leiurus quinquestriatus scorpion venom with a distinct characteristic of binding preferentially to neuroectoderma tumors such as glioma, but not to normal tissue. The overexpression of MUC1, a mucin antigen, in certain cancer cells has been used as an attractive therapeutic target in the design of a drug delivery system consisting of chitosan with a distinct mucoadhesive property. To determine the level of MUC1expression in different cell lines, Cell based Enzyme Linked Immunosorbent Assay (Cell ELISA) was developed for the first time. Attenuated Total Reflectance- Fourier Transform Infra-Red (ATR-FTIR) Spectroscopy is used to investigate the possible molecular interaction between chlorotoxin and glioma cells. This study presents a new approach in monitoring the biochemical and biophysical changes in glioma cells after being exposed to CTX. In addition to characterizing the signature spectra of CTX and glioma cells, we evaluated the differences in biochemical compositions of the spectra of the glioma cells treated with and without CTX over different incubation time periods. The results indicate that the proposed localized drug delivery system with the distinct tumor targeting features and extended release profiles would tune and control the specific delivery of chemotherapeutics in tumor sites.
APA, Harvard, Vancouver, ISO, and other styles
3

Rodríguez, Escalona Gabriela de Jesús. "DEVELOPMENT OF CONTROLLED DRUG DELIVERY SYSTEMS OF POLYMERIC NANOMEDICINES ASSOCIATED TO SCAFFOLDS FOR TISSUE REGENERATION." Doctoral thesis, Universitat Politècnica de València, 2016. http://hdl.handle.net/10251/63231.

Full text
Abstract:
[EN] Nowadays, one of the biggest concerns that permanently keep the attention of main important sectors of human society is health. Modern medical science is compromised with not only providing good adequate treatments but also effective specific solutions for each type of disease or human pathology. In this direction, innovative approaches like tissue engineering or regenerative medicine, controlled drug delivery systems and nanomedicines emerge to bring alternatives to situations hard to solve with conventional treatment and strategies, including the replacement of damaged or diseases tissues and/or organs. Specifically, this research is mainly aimed to design a combined system for controlled, stable and localized release of therapeutic agents that are able to exert their effect selectively on the area that warrants treatment. This construct will have enough versatility to be adapted to almost any kind of treatment, from cancer to tissue regeneration, always that the key requirement of the treatment was the need to provide the treatment of localized, stable and controlled manner. With the purposes of making easier the understanding as well as the design of the system, I was decided, for the proof of concept, to use drugs and materials with known activity applied on tissue regeneration and for the treatment of chronic wounds. The system in question consists of three main elements: 1) The first element is the polymer conjugates of therapeutic agents, which contribute to increasing the selectivity of the therapeutic action of the drug, as well as improved stability, bioavailability and biocompatibility thereof. If the drug is hydrophobic, conjugation contributes to increase its solubility in water, and in the case of proteins used as therapeutic agents, the combination helps reduce the body's immune response, increasing the chance of successful of the treatment. 2) The second element are the biodegradable polymeric microparticles, which in this case act like encapsulation agents for polymeric conjugate , thus allowing to have a second control point in the release kinetics of the therapeutic agents . Simultaneously, the microparticles also play a role in modifying the texture of the final construct, ascribing mechanical and physicochemical properties that help to improve some biological properties of the final material, such as the affinity, adhesion and cell proliferation. 3) The third element consists of a nanoporous membrane made of a biodegradable polymer by electrospinning, which constitute the unifier element of the whole system. This membrane provides manageability to the construct and is itself the last point of control in the release kinetics of the therapeutic agent or agents. Besides, it must be biocompatible and stable at ambient conditions, since this probably is going to be exposed to the environment while protecting the wound, in the case of this kind of application. These three elements, which themselves are complex systems separately, are systematically combined to achieve a synergistic relationship between them so that each one power the qualities of the other two. The resulting construct was characterized and it demonstrated to have characteristic properties that can be used as a control parameter during manufacture of this new material. Also, preliminary biological studies developed "in vitro" indicated that the proposed system may be a good candidate for deeper studies as alternative treatment for chronic wounds and other pathologies that require localized administration for long periods of time.
[ES] Actualmente, una de las mayores preocupaciones que permanentemente laman la atención de los principales sectores de la sociedad humana es la salud. La ciencia médica moderna está comprometida no solo con suministrar tratamientos adecuados, sino más bien ofrecer soluciones efectivas y específicas para cada tipo de enfermedad o patología humana. En este sentido, estrategias innovadoras como la ingeniería de tejidos o la medicina regenerativa, los sistemas de liberación controlada de fármacos y las nanomedicinas, surgen como buenas alternativas para abordar situaciones difíciles de resolver aplicando los tratamientos y estrategias terapéuticas convencionales, como es el caso cuando se hace necesario reemplazar tejidos o incluso órganos dañados por algún traumatismo o enfermedad. Concretamente, el presente trabajo de investigación tiene por objetivo principal diseñar un sistema combinado para la liberación controlada, estable y localizada de agentes terapéuticos que sean capaces de ejercer su efecto de forma selectiva sobre la zona que amerita el tratamiento. Este constructo tendrá la versatilidad suficiente como para poder adaptarse a casi cualquier tipo de tratamiento, desde el cáncer hasta la regeneración de tejido, siempre que el requisito clave del tratamiento sea la necesidad de suministrar el tratamiento de manera localizada, estable y controlada. Para efectos de facilitar la compresión y el diseño del sistema se escogió para la prueba de concepto materiales y fármacos asociados a la regeneración de tejidos, como tratamiento para casos de heridas crónicas. El sistema en cuestión está constituido por tres elementos principales: 1) El primer elemento son los conjugados poliméricos de agentes terapéuticos que contribuirán a aumentar la selectividad de la acción terapéutica del fármaco, así como también a mejora la estabilidad, biodisponibilidad y biocompatibilidad de los mismos. En caso de que el fármaco sea hidrofóbico, la conjugación contribuye a aumentar su solubilidad en agua, y en el caso de usar proteínas como agentes terapéuticos, la conjugación contribuye a disminuir la respuesta inmunológica del cuerpo incrementando las posibilidad de éxito del tratamiento. 2) El segundo elemento son micropartículas poliméricas biodegradables, que en este caso actúan con agentes de encapsulación para los conjugados poliméricos, permitiendo así contar con un segundo punto de control en la cinética de liberación de los agentes terapéuticos. Simultáneamente, las micropartículas también cumplen un papel de modificador de la textura del constructo final, adjudicándole propiedades mecánica y fisicoquímicas que contribuyen a mejorar las propiedades biológicas del material final, como son la afinidad, la adhesión y la proliferación celular. 3) El tercer elemento consiste en una membrana polimérica biodegradable nanoporosa hecha por electrospinning, que constituyen el elemento unificados del sistema, aporta manejabilidad al constructo y es en sí mismo el último punto de control en la cinética de liberación del agente terapéutico. Este último debe ser biocompatible y estable en condiciones ambientales, puesto que probablemente este expuesto al ambiente mientras protege la herida, en el caso concreto de este tipo de aplicación. Estos tres elementos, que en sí mismos constituyen sistemas complejos por separado, se han combinado sistemáticamente para alcanzar una relación sinérgica entre ellos de manera que cada uno potencia las cualidades de los otros dos. El constructo resultante se caracterizó demostrando tener propiedades características que se pueden utilizar como parámetro de control durante la fabricación del mismo. Así mismo estudios in vitro del sistema desarrollado señalan que puede ser un buen candidato para el tratamiento de heridas crónicas entre otras patologías que requieran tratamientos localizados.
[CAT] Actualment, una de les majors preocupacions que permanentment llepen l'atenció dels principals sectors de la societat humana és la salut. La ciència mèdica moderna està compromesa no solament amb subministrar tractaments adequats, sinó més aviat oferir solucions efectives i específiques per a cada tipus de malaltia o patologia humana. En aquest sentit, estratègies innovadores com l'enginyeria de teixits o la medicina regenerativa, els sistemes d'alliberament controlat de fàrmacs i les nanomedicines, sorgeixen com a bones alternatives per a abordar situacions difícils de resoldre aplicant els tractaments i estratègies terapèutiques convencionals, com és el cas quan es fa necessari reemplaçar teixits o fins i tot òrgans danyats per algun traumatisme o malaltia. Concretament, el present treball de recerca té per objectiu principal dissenyar un sistema combinat per a l'alliberament controlat, estable i localitzada d'agents terapèutics que seguen capaços d'exercir el seu efecte de forma selectiva sobre la zona que amirita el tractament. Aquest constructe tindrà la versatilitat suficient com per a poder adaptar-se a quasi qualsevol tipus de tractament, des del càncer fins a la regeneració de teixit, sempre que el requisit clau del tractament sega la necessitat de subministrar el tractament de manera localitzada, estable i controlada. Per a efectes de facilitar la compressió i el disseny del sistema es va escollir per a la prova de concepte materials i fàrmacs associats a la regeneració de teixits, com a tractament per a casos de ferides cròniques. El sistema en qüestió està constituït per tres elements principals: 1) El primer element són els conjugats polimèrics d'agents terapèutics que contribuiran a augmentar la selectivitat de l'acció terapèutica del fàrmac, així com també a millora l'estabilitat, biodisponibilitat i biocompatibilitat dels mateixos. En cas que el fàrmac sega hidrofòbic, la conjugació contribueix a augmentar la seua solubilitat en aigua, i en el cas d'usar proteïnes com a agents terapèutics, la conjugació contribueix a disminuir la resposta immunològica del cos incrementant les possibilitat d'èxit del tractament. 2) El segon element són microparticles polimèriques biodegradables, que en aquest cas actuen amb agents d'encapsulació per als conjugats polimèrics, permetent així comptar amb un segon punt de control en la cinètica d'alliberament de l'agent terapèutics. Simultàniament, les microparticles també compleixen un paper de texturitzant del constructe final, adjudicant-li propietats mecànica i fisicoquímiques que contribueixen a millorar la propietats biològiques del material final, com són l'afinitat, l'adhesió i la proliferació cel·lular. 3) El tercer element consisteix en una membrana polimèrica biodegradable nanoporosa feta per electrospinning, que constitueixen el element unificats del sistema, aporta manejabilitat al constructe i és en si mateix el ultimi punt de control en la cinètica d'alliberament de l'agent terapèutic. Aquest últim ha de ser biocompatible i estable en condicions ambientals, ja que probablement aquest exposat a l'ambient mentre protegeix la ferida, en el cas concret d'aquest tipus d'aplicació. Aquests tres elements que en si mateixos constitueixen sistemes complexos per separat, s'han combinat sistemàticament per a aconseguir una relació sinergètica entre ells de manera que cadascun potencia les qualitats dels altres dos. El constructe resultant es va caracteritzar demostrant tenir propietats característiques que es poden utilitzar com a paràmetre de control durant la fabricació del mateix. Així mateix estudis in vitro del sistema desenvolupat assenyalen que pot ser un bon candidat per al tractament de ferides cròniques entre altres patologies que requeriren tractaments localitzats.
Rodríguez Escalona, GDJ. (2016). DEVELOPMENT OF CONTROLLED DRUG DELIVERY SYSTEMS OF POLYMERIC NANOMEDICINES ASSOCIATED TO SCAFFOLDS FOR TISSUE REGENERATION [Tesis doctoral no publicada]. Universitat Politècnica de València. https://doi.org/10.4995/Thesis/10251/63231
TESIS
APA, Harvard, Vancouver, ISO, and other styles
4

Daniel, Karen D. "An implantable device for localized drug delivery and sensing." Thesis, Massachusetts Institute of Technology, 2009. http://hdl.handle.net/1721.1/46608.

Full text
Abstract:
Thesis (Ph. D.)--Massachusetts Institute of Technology, Dept. of Chemical Engineering, 2009.
Includes bibliographical references (p. 117-120).
There are many potential clinical applications for localized drug delivery and sensing systems, such as cancer, vaccinations, pain management, and hormone therapy. Localized drug delivery systems reduce the amount of drug required for a therapeutic effect and the severity of side effects. Delivery of multiple chemicals has been demonstrated previously from a polymeric microreservoir device. This dime-sized device contains small reservoirs loaded with drug and separated from the outside environment by a degradable polymer membrane. This device was modified to allow minimally invasive implantation with a large-bore needle and has demonstrated in vitro pulsatile release of a model compound after a mock implantation step. A biodegradable sealing method was developed for the polymeric microreservoir device, which makes the device completely resorbable and eliminates the surgical removal step needed with a non-resorbable device. Localized sensing systems will allow early detection of diseases and provide a tool for developing personalized treatment programs. The polymer microchip platform has been combined with magnetic relaxation switch (MRSw) nanoparticle sensors to create an in vivo sensing device. MRSw are magnetic nanoparticles (iron oxide core, crosslinked dextran shell) that can detect a variety of analytes. MRSw are kept in the device by a molecular weight cut-off (MWCO) membrane which allows analytes free access to the nanoparticle sensors.
(cont.) The MRSw aggregate in the presence of the analyte they were designed to detect and this aggregation causes a decrease in the transverse relaxation time (T2), which can be detected with magnetic resonance imaging (MRI) or nuclear magnetic resonance relaxometry. In vitro sensing experiments were used to optimize the device design and characterize its performance. In vivo device-based sensing of hCG, a soluble biomarker that is elevated in testicular and ovarian cancer, has been demonstrated. Cell lines secreting hCG were used to produce ectopic tumors in nude mice. The sensing device was implanted and magnetic resonance imaging (MRI) quantified a T2 decrease in mice with tumors compared to control mice (no tumors). This device may be the first continuous monitoring device for cancer that can be implanted at the tumor site and demonstrates feasibility of MRSw measurements in vivo.
by Karen D. Daniel.
Ph.D.
APA, Harvard, Vancouver, ISO, and other styles
5

Merritt, Sonia Raquel. "Improving surgical efficacy via localized anti-proliferative drug delivery." Case Western Reserve University School of Graduate Studies / OhioLINK, 2014. http://rave.ohiolink.edu/etdc/view?acc_num=case1402017214.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Mulamba, Peter. "Biomaterials Modeling Of Localized Hyperthermia And Drug Delivery For Breast Cancer." The Ohio State University, 2008. http://rave.ohiolink.edu/etdc/view?acc_num=osu1229981884.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mulamba, Peter. "Biomaterials modeling of localized hyperthermia and drug delivery for breast cancer." Columbus, Ohio : Ohio State University, 2009. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1229981884.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Williams, Eva Christabel. "Smart Packaging: A Novel Technique For Localized Drug Delivery For Ovarian Cancer." Scholar Commons, 2012. http://scholarcommons.usf.edu/etd/4257.

Full text
Abstract:
Localized drug delivery is emerging as an effective technique due to its ability to administer therapeutic concentrations and controlled release of drugs to cancer sites in the body. It also prevents the contact of harsh chemotherapy drugs to healthy regions in the body that otherwise would become exposed to current treatments. This study reports on a model chemotherapy drug delivery system comprising non-ionic surfactant vesicles (niosomes) packaged within a temperature-sensitive chitosan network. This smart packaging, or package-within-a package system, provides two distinct advantages. First, the gel prevents circulation of the niosomes and maintains delivery in the vicinity of a tumor. Secondly, the chitosan network protects the niosomes against fluctuations in tonicity, which affects delivery rates. Tonicity is the sum of the concentrations of the solutes which have the capacity to exert an osmotic force across the membrane. Release rates were monitored from both bare niosomes alone and niosome-embedded, chitosan networks. It was observed that chitosan networks prolonged delivery from 100 hours to 55 days in low ionic strength environment and pH conditions similar to a tumor site. The primary effect of chitosan is to add control on release time and dosage, and stabilize the niosomes through a high ionic strength surrounding that prevents uncontrolled bursting of the niosomes. Secondary factors include cross-link density of the chitosan network, molecular weight of the individual chitosan polymers, dye concentration within the niosomes, and the number density of niosomes packaged within the chitosan network. Each of these factors can be altered to fine-tune release rates. Release rate experiments were conducted with 5,6-carboxyfluorescein, a fluorescent dye and chemotherapeutics paclitaxel and carboplatin. In vitro studies showed a preferential affinity of the smart packaged system to ovarian carcinoma cell line OV2008 as compared to normal epithelial cell lines of Ilow and MCC3. Further, feasibility of the drug delivery system was evaluated in vivo. Toxicity studies revealed that the system was non-toxic and feasible in vivo. The final outcome of this study includes tuning of the variables mentioned above that will contribute to the development of low cost and improved methods for drug delivery with application to intracavitary ovarian cancer treatment and other types of cancer
APA, Harvard, Vancouver, ISO, and other styles
9

Leach, Jeffrey Harold. "Magnetic Targeted Drug Delivery." Thesis, Virginia Tech, 2003. http://hdl.handle.net/10919/31261.

Full text
Abstract:
Methods of guiding magnetic particles in a controlled fashion through the arterial system in vivo using external magnetic fields are explored. Included are discussions of applications, magnetic field properties needed to allow guiding based on particle characteristics, hemodynamic forces, the uniformity of field and gradients, variable tissue characteristics, and imaging techniques employed to view these particles while in transport. These factors influence the type of magnetic guidance system that is needed for an effective drug delivery system. This thesis reviews past magnetic drug delivery work, variables, and concepts that needed to be understood for the development of an in vivo magnetic drug delivery system. The results of this thesis are the concise study and review of present methods for guided magnetic particles, aggregate theoretical work to allow proper hypotheses and extrapolations to be made, and experimental applications of these hypotheses to a working magnetic guidance system. The design and characterization of a magnetic guidance system was discussed and built. The restraint for this system that balanced multiple competing variables was primarily an active volume of 0.64 cm3, a workspace clearance of at least an inch on every side, a field of 0.3T, and a local axial gradient of 13 T/m. 3D electromagnetic finite element analysis modeling was performed and compared with experimental results. Drug delivery vehicles, a series of magnetic seeds, were successfully characterized using a vibrating sample magnetometer. Next, the magnetic seed was investigated under various flow conditions in vitro to analyze the effectiveness of the drug delivery system. Finally, the drug delivery system was successfully demonstrated under limiting assumptions of a specific magnetic field and gradient, seed material, a low fluid flow, and a small volume.
Master of Science
APA, Harvard, Vancouver, ISO, and other styles
10

Nikam, Shantanu P. "LOCALIZED ANTIBIOTIC DELIVERY VIA VALINE BASED POLY(ESTER UREA)." University of Akron / OhioLINK, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=akron1522931095020122.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Localized Drug Delivery System"

1

Jain, Kewal K., ed. Drug Delivery System. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0363-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Drug delivery system. New York: Humana Press, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Shah, Nirmal, ed. Nanocarriers: Drug Delivery System. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-33-4497-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Jain, Kewal K., ed. Drug Delivery to the Central Nervous System. Totowa, NJ: Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-529-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

F, Smolen Victor, and Ball LuAnn, eds. Bioavailability control by drug delivery system design. New York: Wiley, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Parfenyuk, E. V. Silica nanoparticles as drug delivery system for immunomodulator GMDP. New York, N.Y: ASME, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

David, Ganderton, Jones T. M. 1942-, Pharmaceutical Society of Great Britain., and King's College (University of London). Chelsea Dept. of Pharmacy., eds. Drug delivery to the respiratory tract. Weinheim, Federal Republic of Germany: VCH, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Geest, Ronald van der. PK/PD based drug delivery system design: Iontophoretic apomorphine delivery in patients with Parkinson's disease. [Leiden: University of Leiden], 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Cheng, Erik Ho Yan. Combination of hydrogel and liposomes as a responsive drug delivery system. Ottawa: National Library of Canada = Bibliothèque nationale du Canada, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Sharma, Hari S., Dafin F. Muresanu, and Aruna Sharma, eds. Drug and Gene Delivery to the Central Nervous System for Neuroprotection. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-57696-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Localized Drug Delivery System"

1

Marotta, James S. "Drug Delivery Systems for Localized Treatment of Disease." In Biomedical Devices and Their Applications, 33–60. Berlin, Heidelberg: Springer Berlin Heidelberg, 2004. http://dx.doi.org/10.1007/978-3-662-06108-4_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Campbell, Scott, and Niels Smeets. "Drug Delivery: Localized and Systemic Therapeutic Strategies with Polymer Systems." In Polymers and Polymeric Composites: A Reference Series, 1079–134. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-95987-0_32.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Campbell, Scott, and Niels Smeets. "Drug Delivery: Localized and Systemic Therapeutic Strategies with Polymer Systems." In Polymers and Polymeric Composites: A Reference Series, 1–56. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-92067-2_32-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Eppstein, Deborah A., Marjorie A. van der Pas, Brian B. Schryver, Philip L. Felgner, Carol A. Gloff, and Kenneth F. Soike. "Controlled-Release and Localized Targeting of Interferons." In Delivery Systems for Peptide Drugs, 277–83. Boston, MA: Springer US, 1986. http://dx.doi.org/10.1007/978-1-4757-9960-6_24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ibsen, Stuart, Michael Benchimol, Dmitri Simberg, and Sadik Esener. "Ultrasound Mediated Localized Drug Delivery." In Nano-Biotechnology for Biomedical and Diagnostic Research, 145–53. Dordrecht: Springer Netherlands, 2011. http://dx.doi.org/10.1007/978-94-007-2555-3_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Weaver, James C., Robert Langer, and Russell O. Potts. "Tissue Electroporation for Localized Drug Delivery." In Electromagnetic Fields, 301–16. Washington, DC: American Chemical Society, 1995. http://dx.doi.org/10.1021/ba-1995-0250.ch017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Makino, Kimiko. "Drug Delivery System." In Electrical Phenomena at Interfaces and Biointerfaces, 709–23. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2012. http://dx.doi.org/10.1002/9781118135440.ch40.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Godin, Biana, Elka Touitou, Rajaram Krishnan, Michael J. Heller, Nicolas G. Green, Hossein Nili, David J. Bakewell, et al. "Drug Delivery System." In Encyclopedia of Nanotechnology, 587. Dordrecht: Springer Netherlands, 2012. http://dx.doi.org/10.1007/978-90-481-9751-4_100192.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Yang, Qiuhong, and Laird Forrest. "Drug Delivery to the Lymphatic System." In Drug Delivery, 503–48. Hoboken, NJ: John Wiley & Sons, Inc, 2016. http://dx.doi.org/10.1002/9781118833322.ch21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

On, Ngoc H., Vinith Yathindranath, Zhizhi Sun, and Donald W. Miller. "Pathways for Drug Delivery to the Central Nervous System." In Drug Delivery, 353–82. Hoboken, NJ: John Wiley & Sons, Inc, 2016. http://dx.doi.org/10.1002/9781118833322.ch16.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Localized Drug Delivery System"

1

Wiranowska, Marzenna, Ryan Toomey, Rana Falahat, and Norma Alcantar. "Abstract 3615: Design for a flexible localized drug delivery system." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-3615.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Wiranowska, Marzenna, Ryan Toomey, Rana Falahat, and Norma Alcantar. "Abstract 3615: Design for a flexible localized drug delivery system." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-3615.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ban, Jae-won, Kyo-in Koo, Sunkil Park, Gilsub Kim, and Dong-il “Dan” Cho. "Micro-Injection System for Localized Drug Delivery Using Embedded Solid Chemical Propellant." In 2007 Frontiers in the Convergence of Bioscience and Information Technologies. IEEE, 2007. http://dx.doi.org/10.1109/fbit.2007.110.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Williams, Eva Christabel, Marzenna Wiranowska, Ryan Toomey, and Norma Alcantar. "Abstract 3229: Thermo-responsive double packaged system for localized drug delivery for cancer treatment." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-3229.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Keyes, Joseph T., Bruce R. Simon, and Jonathan P. Vande Geest. "Transport in Pulsatile Axisymmetric Stented Arterial Models From Location-Dependent Variations in Permeability and Mechanical Properties." In ASME 2011 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2011. http://dx.doi.org/10.1115/sbc2011-53998.

Full text
Abstract:
Drug-eluting stents (DESs) perform their antiproliferative effects through the use of localized drug delivery. The delivery may be computationally modeled to determine efficacy of the DES-tissue system and utilizes coupled convective and diffusive transport. Since the movement of solutes through the wall is via the coupled effects of convective and diffusive transport, the relative influence of these factors provides insight into the governing forces of localized DES drug delivery [1].
APA, Harvard, Vancouver, ISO, and other styles
6

Ridgeway, Shane, Junho Song, and Li Cao. "A Selectively Anodic Bonded Micropump for Implantable Medical Drug Delivery Systems." In ASME 2002 International Mechanical Engineering Congress and Exposition. ASMEDC, 2002. http://dx.doi.org/10.1115/imece2002-33551.

Full text
Abstract:
Microelectromechanical Systems (MEMS) fabrication techniques offer a unique solution for implantable medical drug delivery systems. An implantable medical drug delivery system can relieve the pain associated with frequent injections and deliver a localized dosage. An implantable drug delivery system can also avoid contamination and infection better than conventional injection methods (such as intravenous injection). The major advantage of microfabricated drug delivery systems is the possibility of mass production at low cost. A silicon based peristaltically actuated implantable medical drug delivery system consisting of three pumping chambers was microfabricated and tested. The unique features of this microfabricated drug delivery system include the design of a selectively anodic bonded micropump. The selectively anodic bonded Pyrex glass wafer was used to seal the pump chambers and allow for a view of fluid movement. Chromium was used as a selective bonding material. A 20 nm thick chromium film deposited on the top surface of the silicon valves successfully prevented bonding between the valve and the glass wafer. The pump operates with a normally closed valve which consists of a silicon mesa located at the center of each chamber. This mesa makes intimate contact with the glass wafer. Three 180 μm deep and 12 mm diameter circular chambers were etched into the top surface of the silicon wafer using deep reactive ion etching (DRIE) and connected by two 1 mm wide channels. Directly opposite the chambers, three 12 mm diameter circular features were etched 320 μm deep using DRIE to create a 50 μm thick silicon membrane and provide an attachment point for piezoelectric actuating disks. The piezoelectric disks were applied using a conductive silver epoxy. A positive potential was applied to the gold layer that was e-beam deposited on the substrate, with the negative terminal applied to each individual actuator. The three pump chambers were actuated in a peristaltic motion with driving frequencies ranging from 0.5 to 4 Hz and actuation voltages ranging from 10–130 V. The design goal of 10 μL/min was met at driving frequencies of 2 and 4 Hz where the maximum flowrate was 10.1 and 11.4 μL/min for the 2 and 4 Hz actuation frequencies respectively at an actuation voltage of 130 V. The maximum pressure achieved by the pump was 35.8 mmH20 for the 2 and 4 Hz actuation frequencies at an actuation voltage of 130 V.
APA, Harvard, Vancouver, ISO, and other styles
7

Ma, Bin, Sheng Liu, Zhiyin Gan, Guojun Liu, Xincia Cai, Honghai Zhang, and Zhigang Yang. "A PZT Insulin Pump Integrated With Silicon Needle Array for Transdermal Delivery." In ASME 4th International Conference on Nanochannels, Microchannels, and Minichannels. ASMEDC, 2006. http://dx.doi.org/10.1115/icnmm2006-96005.

Full text
Abstract:
Many of the compounds in drugs cannot be effectively delivered using current drug delivery techniques (e.g., pills and injections). Transdermal delivery is an attractive alternative, but it is limited by the extremely low permeability of the skin. Because the primary barrier to transport is located in the upper tissue, Micro-Electro-Mechanical-System (MEMS) technology provides novel means in terms of both micro needle array and PZT pump, with the former one to increase permeability of human skin with efficiency, safety and painless delivery, and the latter one to decrease the size of the pump. Micro needle array has many advantages, including minimal trauma at penetration site due to the small size in needle, no condition limit, painless drug delivery for penetration depth with few nerves, and precise control of penetration depth for micro needle extension length. The micro needle array drug delivery is precise, painless, effective, clean and neatness, without any inconvenience. This will promote the development of biomedical sciences and technology and makes medical devices more humanized. So far most of the insulin pump has been using mechanical pump. We present the first development of this novel technology which can assemble the PZT pump and the micro needles together for diabetes mellitus. The micro needle array based on a flexible substrate can be mounted on non-planar surface or even on flexible objects such as a human fingers and arms. The PZT pump can pump the much more precision drug accurately than mechanical pump and the overall size is much smaller than those mechanical pumps. The hollow wall straight micro needle array is fabricated on a flexible silicon substrate by inductively coupled plasma (ICP) and anisotropic wet etching techniques. The fabricated hollow micro needles are 200μm in length and 30μm in diameter. The micro needle array, which may be built with on-board fluid pumps, have potential applications in the chemical and biomedical fields for localized chemical analysis, programmable drug-delivery systems, and very small, precise fluids sampling. The micro needle array has been installed in an insulin pump for demonstration and a leak free packaging is introduced.
APA, Harvard, Vancouver, ISO, and other styles
8

Williams, Eva C., Ryan Toomey, Marcia Gordon, Donald Williams, Dave Morgan, and Norma Alcantar. "Abstract 3707: Design and characterization of a double packaged system for localized drug delivery for the treatment of cancers." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-3707.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Keyes, Joseph T., Leonardo G. Montilla, Russel S. Witte, and Jonathan P. Vande Geest. "Retention and Transport of Hydrophobic and Hydrophilic Drug Surrogate Molecules in Coronary Arteries Measured Nondestructively With Photoacoustic Ultrasound." In ASME 2013 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/sbc2013-14626.

Full text
Abstract:
The design and implementation of local drug delivery mechanisms in cardiovascular applications provides a method by which localized action can occur without potentially problematic systemic effects. This has been especially relevant in the case of drug-eluting stents (DESs). It has been previously shown that the degree of chemical polarization can significantly change the degree of transport and the degree of vascular retention of drugs. Understanding how these differences occur in real-time, and nondestructively, can better help guide the design of such pharmaceuticals. Previous work by our laboratory has indicated differences in transport based on location within the coronary tree (Fig. 1) [1].
APA, Harvard, Vancouver, ISO, and other styles
10

Starly, Binil, Shih-Feng Lan, and David Schmidtke. "Customized Release of Metronidazole From Composite Casted Rings of Poly-Caprolactone/Alginate for Periodontal Drug Delivery." In ASME 2013 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/sbc2013-14177.

Full text
Abstract:
Dental implants provide support for dental crowns and bridges by serving as abutments for the replacement of missing teeth. The objective of this study was to demonstrate a novel method of controlled localized delivery of antibacterial agents to an implant site using a custom fabricated ring. The study involved incorporating a model antibacterial agent (metronidazole) into custom designed Poly-ε-Caprolactone/Alginate (PCL/Alginate) composite rings to produce the intended controlled release profile. In vitro release studies indicate that pure (100%) alginate rings exhibited an expected burst release of metronidazole in the first few hours, whereas Alginate/PCL composite rings produced a medium burst release followed by a sustained release for a period greater than 4 weeks. By varying the PCL/Alginate weight ratios, we have shown that we can control the amount of antibacterial agents released to provide the minimal inhibitory concentration needed for adequate protection. The developed system demonstrates a controllable drug release profile and the potential for the ring to inhibit bacterial biofilm growth for the prevention of diseases such as peri-implantitis resulting from bacterial infection at the implant site.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Localized Drug Delivery System"

1

McPhillips, D. M., M. W. Price, J. W. Gibson, and R. A. Casper. Development of an On-Demand, Generic, Drug-Delivery System. Fort Belvoir, VA: Defense Technical Information Center, August 1985. http://dx.doi.org/10.21236/ada158550.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Pflugfelder Ghanashyam S., Stephen C. Broadly Applicable Nanowafer Drug Delivery System for Treating Eye Injuries. Fort Belvoir, VA: Defense Technical Information Center, September 2014. http://dx.doi.org/10.21236/ada613401.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dash, Alekha K. Novel in Situ Gel Drug Delivery System for Breast Cancer Treatment. Fort Belvoir, VA: Defense Technical Information Center, July 2007. http://dx.doi.org/10.21236/ada474685.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Deluca, Patrick P. Development of a Sustained Antiplague, Antimicrobial Delivery System for KSL Localized in the Oral Cavity. Fort Belvoir, VA: Defense Technical Information Center, May 2004. http://dx.doi.org/10.21236/ada428511.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Sledge, George W. Nanoparticle: Monoclonal Antibody Conjugates: A Novel Drug Delivery System in Human Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, May 2002. http://dx.doi.org/10.21236/ada420569.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sledge, George. Nanoparticle: Monoclonal Antibody Conjugates: A Novel Drug Delivery System in Human Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, May 2000. http://dx.doi.org/10.21236/ada393348.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Basu, Sayani. Nanoparticle-Based Therapeutics for the Treatment of Stroke. Nature Library Ltd, November 2020. http://dx.doi.org/10.47496/nl.blog.13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Munhuweyi, Ngonidzashe Portia, Zita Ekeocha, Stephen Robert Byrn, and Kari L. Clase. Resource Modelling for the QC Laboratory at XYZ Pharmaceuticals in Southern Africa. Purdue University, November 2021. http://dx.doi.org/10.5703/1288284317431.

Full text
Abstract:
Quality control (QC) laboratories are critical components in drug manufacturing and running them efficiently contributes to better, consistent supply of cost-effective quality products, while also and preventing deaths due to untimely delivery or unavailability of medicines. Having a resource modelling tool to estimate resources needed to handle a particular demand in a given system is essential for efficient running of QC laboratory. This study was done to establish such a model at XYZ Pharmaceuticals. The list of all products manufactured by XYZ Pharmaceuticals Southern Africa was reviewed; and product families for all products were identified. Analysts’ hands on time (HOT) to process one sample of each of the product families was estimated. The number of analysts required to support the workload at XYZ Pharmaceuticals was calculated using the HOTs for the different product families and the Maslaton’s Calculation Model. A baseline resource model was established.
APA, Harvard, Vancouver, ISO, and other styles
9

Perceptions of community pharmacists, patent and proprietary medicine vendors, and their clients regarding quality of family planning services: The IntegratE Project. Population Council, 2021. http://dx.doi.org/10.31899/rh17.1016.

Full text
Abstract:
The IntegratE Project is a four-year initiative (2017–21) implemented by the Population Council and partners that seeks to increase access to contraceptive methods by involving the private sector (community pharmacists [CPs] and patent and proprietary medicine vendors [PPMVs]) in family planning (FP) service delivery in Lagos and Kaduna States, Nigeria. The project aims to establish a regulatory system with the Pharmacists Council of Nigeria to ensure that CPs and PPMVs provide quality FP services, comply with FP regulations, and report service statistics to the Health Information Management System (HMIS). To achieve this, the project is implementing: a pilot three-tiered accreditation system for PPMVs; a supervisory model to ensure standard drug-stocking practices; building the capacity of CPs and PPMVs to provide a wider range of FP services and data report to the HMIS. This brief focuses on quality of care received by women voluntarily seeking FP services from CPs and PPMVs. CPs and PPMVs and their clients appear to be satisfied with the FP services offered by CPs and PPMVs; on-going learning opportunities, and a supportive supervision system that is properly coordinated should be sufficient to maintain the quality of services offered by CPs and PPMVs.
APA, Harvard, Vancouver, ISO, and other styles
10

IntegratE Project results: Family planning knowledge and quality of care received from community pharmacists and patent and proprietary medicine vendors. Population Council, 2021. http://dx.doi.org/10.31899/sbsr2021.1018.

Full text
Abstract:
In Nigeria, Community Pharmacists (CPs) and Patent and Proprietary Medicine Vendors (PPMVs) are the first point of care for many common illnesses. Although CPs and PPMVs are not formally recognized as family planning (FP) service providers, 22% of modern contraceptive users report receiving their last method from a PPMV and 12% from a private pharmacy. PPMVs are popular for FP because of their widespread availability, consistent drug stocks, extended hours, personable interactions, and lack of separate fees for consultations. As the Federal Ministry of Health explores expanding its task sharing policy to include CPs and PPMVs, evidence is needed on an effective regulatory system to support CPs and PPMVs in providing high-quality FP services. The IntegratE Project (2017-21) seeks to increase access to contraceptive methods by involving the private sector in FP service delivery in Lagos and Kaduna states. The Project seeks to establish a regulatory system with the Pharmacists Council of Nigeria to ensure that CPs and PPMVs provide quality FP services and comply with regulations. To achieve this, the Project is implementing a pilot accreditation system for PPMVs. CPs function outside the pilot accreditation system but would receive the same training. This brief compares knowledge of FP and quality of care received among PPMVs and CPs as reported by FP clients served.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Localized Drug Delivery System' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography